Inpatient Use of Personal Continuous Glucose Monitor (CGM) to Improve Diabetes Mellitus Control (NCT07006480)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this research is to prove that data generated by your real-time personal continuous glucose monitors CGMs brought in the hospital at the time of hospitalization can be monitored and safely used to guide insulin therapy aiming to improve glycemic control and to diminish the hypoglycemia and hyperglycemia episodes without negatively affecting patients' satisfaction, providers and your nurses satisfaction with how glucose is monitored and treated in the hospital.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (14 items).
Location: Mayo Clinic in Florida — Jacksonville, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Participants unable to provide informed medical consent.
- Participants admitted to Intensive Care Units (ICU). Enrollment is possible after transferring out of the ICU.
- Actively being treated for DKA (diabetes ketoacidosis) or HHS (hyperosmolar hyperglycemic state)
- Patients with a diagnosis of liver cirrhosis.
- Patients with a diagnosis of ESRD or Acute Renal Failure on hemodialysis or peritoneal dialysis.
- Patients with planned MRI or surgical procedure. Enrollment is possible after MRI or surgery.
- Participants with allergy to medical grade adhesive or medical tape.
- Participants who are pregnant, wanting to become pregnant, or nursing during study period.
- Participants using Medtronic and Dexcom sensors and taking acetaminophen more than 4g per day or more than 1gm every 6 hours.
- Participants using Dexcom sensors and taking hydroxyurea.
- Participants using Libre sensors and taking over 500 mg of ascorbic acid.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (1 Sites)
- Mayo Clinic in Florida — Jacksonville, Florida
📞 Contact the Study Coordinator
Phone: (904) 953-2000
Email: dumitrascu.adrian@mayo.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Diabetes Mellitus
- Early Tracking of Childhood Health Determinants (ETCHED) Study — Phoenix, Arizona
- Gemini Study: A Prospective, Multicenter Evaluation of Performance and Safety of the Eversense Gemini System With Flash Glucose Measurement Feature — Escondido, California
- Examining the Effectiveness of DermGEN™ in the Treatment of Diabetic Foot Ulcers in First Nations People — Emo, Ontario
- Effectiveness of an Inpatient Rehabilitation and Prosthetic Training Model in Patients With Vascular and Metabolic Transfemoral Amputation — Mexico City, Mexico City
- Support-t Online Training in Youth Living With Type 1 Diabetes Transitioning to Adult Care — Gatineau,
- The REST Study for CGM Use in Older Adults With Insulin-treated Diabetes — Boston, Massachusetts
Explore by condition: All Diabetes Mellitus clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.